PMID- 37431351
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231102
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 6
DP  - 2023 Jun
TI  - Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide 
      Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose 
      Monitoring Data: A Retrospective Cohort Study From Eastern India.
PG  - e40179
LID - 10.7759/cureus.40179 [doi]
LID - e40179
AB  - INTRODUCTION: Oral semaglutide is a glucagon-like peptide-1 receptor 
      agonist (GLP-1RA) class of antidiabetic medication. High costs and GI side 
      effects are the major limitations of its widespread use. Some patients who were 
      on a 14 mg dose of oral semaglutide self-prescribed an alternate-day schedule to 
      mitigate GI side effects and to reduce the cost. METHODS: This retrospective 
      observational cohort study evaluates the ambulatory glucose profile (AGP) data, 
      extrapolated glycosylated hemoglobin (HbA1C), and BMI of 11 types of 2 diabetes 
      mellitus (T2DM) while they were on an alternate-day 14 mg dose of oral 
      semaglutide compared to their record while on a daily 7 mg dose. The AGP metrics 
      (time-in-range (TIR), time-below-range (TBR), and time-above-range (TAR)) along 
      with extrapolated HbA1C and BMI were analyzed. Statistical analysis was done 
      using SPSS Statistics version 21.0. RESULTS: No statistically significant 
      difference in the AGP metrics between the AGP profile of a daily 7 mg dose and 
      the AGP profile of an alternate-day 14 mg dose of oral semaglutide was observed. 
      Interestingly, a statistically significant progressive decline in BMI value was 
      observed even on the alternate-day 14 mg dose when compared to the daily 7 mg 
      dose. CONCLUSION: In this small cohort of patients, the metrics of short-term 
      glycemic control and the extrapolated HbA1C values were similar for the daily 7 
      mg dose versus the alternate-day 14 mg dose of oral semaglutide. BMI showed 
      progressive reduction which was statistically significant even with the 
      alternate-day 14 mg dose of oral semaglutide.
CI  - Copyright (c) 2023, RoyChaudhuri et al.
FAU - RoyChaudhuri, Soumyabrata
AU  - RoyChaudhuri S
AD  - Diabetes and Endocrinology, Kali Prasad Chowdhury Medical College and Hospital, 
      Kolkata, IND.
FAU - Majumder, Anirban
AU  - Majumder A
AD  - Diabetes and Endocrinology, Kali Prasad Chowdhury Medical College and Hospital, 
      Kolkata, IND.
FAU - Mukherjee, Poulomi
AU  - Mukherjee P
AD  - Community Medicine, Medical College and Hospital, Kolkata, IND.
FAU - Sanyal, Debmalya
AU  - Sanyal D
AD  - Diabetes and Endocrinology, Kali Prasad Chowdhury Medical College and Hospital, 
      Kolkata, IND.
FAU - Chakraborty, Soma
AU  - Chakraborty S
AD  - Diabetes and Endocrinology, Diabetes-Obesity-Thyroid-Hormone Clinic, Kolkata, 
      IND.
FAU - Chuyan, Susama
AU  - Chuyan S
AD  - Diabetes and Endocrinology, Adopt Endocrine, Kolkata, IND.
LA  - eng
PT  - Journal Article
DEP - 20230609
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10329815
OTO - NOTNLM
OT  - ambulatory glucose profile (agp)
OT  - body mass index (bmi)
OT  - glycaemic control
OT  - oral semaglutide
OT  - types 2 diabetes
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2023/07/11 06:42
MHDA- 2023/07/11 06:43
PMCR- 2023/06/09
CRDT- 2023/07/11 03:35
PHST- 2023/06/09 00:00 [accepted]
PHST- 2023/07/11 06:43 [medline]
PHST- 2023/07/11 06:42 [pubmed]
PHST- 2023/07/11 03:35 [entrez]
PHST- 2023/06/09 00:00 [pmc-release]
AID - 10.7759/cureus.40179 [doi]
PST - epublish
SO  - Cureus. 2023 Jun 9;15(6):e40179. doi: 10.7759/cureus.40179. eCollection 2023 Jun.